Literature DB >> 19264698

Rituximab and omalizumab in severe, refractory insulin allergy.

Patrick F K Yong, Rifat Malik, Sefina Arif, Mark Peakman, Stephanie Amiel, Mohammad A A Ibrahim, Andrew Gough.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19264698     DOI： 10.1056/NEJMc0808282

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

Review 1.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

2.  Insulin allergy: a diagnostic and therapeutic strategy based on a retrospective cohort and a case-control study.

Authors:  Agnès Sola-Gazagnes; Catherine Pecquet; Stefano Berré; Peter Achenbach; Laure-Anne Pierson; Isabelle Virmoux-Buisson; Jocelyne M'Bemba; Fabienne Elgrably; Philippe Moguelet; Christian Boitard; Sophie Caillat-Zucman; Moussa Laanani; Joel Coste; Etienne Larger; Roberto Mallone
Journal:  Diabetologia       Date:  2022-05-04       Impact factor: 10.460

Review 3.  Novel Biologicals for the Treatment of Allergic Diseases and Asthma.

Authors:  Hern-Tze Tina Tan; Kazunari Sugita; Cezmi A Akdis
Journal:  Curr Allergy Asthma Rep       Date:  2016-10       Impact factor: 4.806

Review 4.  Allergic reactions to human insulin: a review of current knowledge and treatment options.

Authors:  Baris Akinci; Serkan Yener; Firat Bayraktar; Sena Yesil
Journal:  Endocrine       Date:  2009-10-30       Impact factor: 3.633

Review 5.  Therapies for allergic inflammation: refining strategies to induce tolerance.

Authors:  Cezmi A Akdis
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

Review 6.  Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

Authors:  David Aguirre-Valencia; Iván Posso-Osorio; Juan-Carlos Bravo; Fabio Bonilla-Abadía; Gabriel J Tobón; Carlos A Cañas
Journal:  Clin Rheumatol       Date:  2017-07-31       Impact factor: 2.980

7.  Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy.

Authors:  Claudia Cavelti-Weder; Bettina Muggli; Cornelia Keller; Andrea Babians-Brunner; Anna Biason-Lauber; Marc Y Donath; Peter Schmid-Grendelmeier
Journal:  Diabetes Care       Date:  2012-06       Impact factor: 19.112

8.  Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study.

Authors:  Hanneke N G Oude Elberink; Mathilde Jalving; Hilda Dijkstra; Annick A J M van de Ven
Journal:  Clin Transl Allergy       Date:  2020-01-29       Impact factor: 5.871

Review 9.  Hypersensitivity reactions to human insulin analogs in insulin-naïve patients: a systematic review.

Authors:  Andrew S Bzowyckyj; Amanda M Stahnke
Journal:  Ther Adv Endocrinol Metab       Date:  2017-12-26       Impact factor: 3.565

10.  Insulin allergy can be successfully managed by a systematic approach.

Authors:  Maija Bruun Haastrup; Jan Erik Henriksen; Charlotte Gotthard Mortz; Carsten Bindslev-Jensen
Journal:  Clin Transl Allergy       Date:  2018-09-25       Impact factor: 5.871
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.